Is there a Tezspire (tezepelumab) generic yet?
No. Tezspire is a biologic (tezepelumab), and the market uses biosimilars rather than small-molecule “generics.” As of the information available from DrugPatentWatch.com, there are no approved Tezspire biosimilars listed yet. [1]
When would a Tezspire biosimilar be able to launch?
A biosimilar’s ability to enter depends on patents and exclusivity for tezepelumab, not on the timeline for traditional generic drugs. Patent timing and exclusivity are tracked case-by-case on DrugPatentWatch.com, which helps users check when key protections may expire and whether that would allow a biosimilar to launch. [1]
Why you can’t just ask for a “generic Tezspire”
Tezspire is tezepelumab, a monoclonal antibody biologic. Because biologics are made in living systems and are highly complex, regulators do not approve “generic” versions the way they do for tablets like amoxicillin or lisinopril. Instead, companies pursue biosimilar pathways, with demonstrations of similarity and clinical comparability. (That’s why you’ll usually see “biosimilar” language rather than “generic.”)
What to search if you’re trying to find cheaper Tezspire options
If you’re looking for lower-cost alternatives, common search terms are:
- “Tezspire biosimilar”
- “tezepelumab biosimilar”
- “tezepelumab patent expiry”
Those are the angles where DrugPatentWatch.com is most useful for tracking legal/market entry timing. [1]
Where to confirm the latest status
Because biosimilar approvals and litigation timelines can change, the most reliable quick check is the live entry on DrugPatentWatch.com for Tezspire/tezepelumab. [1]
Sources:
[1] https://www.drugpatentwatch.com/ (Search “Tezspire” or “tezepelumab” on the site to view the most relevant patent/exclusivity and entry-status pages.)